We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK shares have set a fresh low for the year, falling 49p to 1402p even though its core earnings figure of 49.7p a share beat ...

Seeking Alpha analyst and Investing Group leader, Manika Premsingh believes the worst is now behind GSK, adding that even though there is risk to core EPS growth of forecasts 10-12% for the full ...

GSK cuts 2024 vaccine sales forecast for second ... compared with estimates of 43.6 pence on sales of about 8 billion pounds. It kept full-year total sales and earnings forecasts unchanged.

GSK has also taken the opportunity to throw out some of research products that were not producing results. Development of a PI3kb inhibitor, GSK2636771, has been terminated as part of the R&D rethink.

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...